Existence of a microRNA pathway in anucleate platelets P Landry, I Plante, DL Ouellet, MP Perron, G Rousseau, P Provost Nature structural & molecular biology 16 (9), 961, 2009 | 577 | 2009 |
RNAi and small interfering RNAs in human disease therapeutic applications MR Lares, JJ Rossi, DL Ouellet Trends in biotechnology 28 (11), 570-579, 2010 | 348 | 2010 |
Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element DL Ouellet, I Plante, P Landry, C Barat, MÈ Janelle, L Flamand, ... Nucleic acids research 36 (7), 2353-2365, 2008 | 288 | 2008 |
MicroRNAs in gene regulation: when the smallest governs it all DL Ouellet, MP Perron, LA Gobeil, P Plante, P Provost Journal of Biomedicine and Biotechnology 2006, 2006 | 169 | 2006 |
Dicer-derived microRNAs are utilized by the fragile X mental retardation protein for assembly on target RNAs I Plante, L Davidovic, DL Ouellet, LA Gobeil, S Tremblay, EW Khandjian, ... Journal of Biomedicine and Biotechnology 2006, 2006 | 162 | 2006 |
Dicer-Derived MicroRNA< small. letters> s Are Utilized by the Fragile X Mental Retardation Protein for Assembly on Target RNA< small. letters> s I Plante, L Davidovic, DL Ouellet, LA Gobeil, S Tremblay, EW Khandjian, ... BioMed Research International 2006, 0 | 162* | |
The N-terminal half of the core protein of hepatitis C virus is sufficient for nucleocapsid formation N Majeau, V Gagne, A Boivin, M Bolduc, JA Majeau, D Ouellet, D Leclerc Journal of general virology 85 (4), 971-981, 2004 | 98 | 2004 |
Efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method JP Iyombe-Engembe, DL Ouellet, X Barbeau, J Rousseau, ... Molecular Therapy-Nucleic Acids 5, e283, 2016 | 96 | 2016 |
CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo BL Duchêne, K Cherif, JP Iyombe-Engembe, A Guyon, J Rousseau, ... Molecular Therapy 26 (11), 2604-2616, 2018 | 73 | 2018 |
Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia DL Ouellet, K Cherif, J Rousseau, JP Tremblay Gene therapy 24 (5), 265-274, 2017 | 68 | 2017 |
Regulation of host gene expression by HIV-1 TAR microRNAs DL Ouellet, J Vigneault-Edwards, K Létourneau, LA Gobeil, I Plante, ... Retrovirology 10 (1), 1-15, 2013 | 60 | 2013 |
Human Dicer C-terminus functions as a 5-lipoxygenase binding domain V Dincbas-Renqvist, G Pépin, M Rakonjac, I Plante, DL Ouellet, ... Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1789 (2), 99-108, 2009 | 58 | 2009 |
Current knowledge of MicroRNAs and noncoding RNAs in virus-infected cells DL Ouellet, P Provost RNA Interference, 35-65, 2010 | 36 | 2010 |
Regulatory RNAs MP Perron, V Boissonneault, LA Gobeil, DL Ouellet, P Provost Target Discovery and Validation Reviews and Protocols, 311-326, 2007 | 36 | 2007 |
Emergence of a complex relationship between HIV-1 and the microRNA pathway DL Ouellet, I Plante, C Barat, MJ Tremblay, P Provost siRNA and miRNA Gene Silencing, 1-19, 2009 | 30 | 2009 |
Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy J Chung, J Zhang, H Li, DL Ouellet, DL DiGiusto, JJ Rossi Human gene therapy 23 (11), 1200-1208, 2012 | 27 | 2012 |
Development of an AAV9 coding for a 3XFLAG-TALE frat# 8-VP64 able to increase in vivo the human frataxin in YG8R mice P Chapdelaine, C Gérard, N Sanchez, K Cherif, J Rousseau, DL Ouellet, ... Gene therapy 23 (7), 606-614, 2016 | 24 | 2016 |
Increased frataxin expression induced in friedreich ataxia cells by platinum TALE-VP64s or platinum TALE-SunTag K Cherif, C Gérard, J Rousseau, DL Ouellet, P Chapdelaine, JP Tremblay Molecular Therapy-Nucleic Acids 12, 19-32, 2018 | 17 | 2018 |
Nucleolar localization of HIV-1 Rev is required, yet insufficient for production of infectious viral particles JAC Arizala, M Takahashi, JC Burnett, DL Ouellet, H Li, JJ Rossi AIDS research and human retroviruses 34 (11), 961-981, 2018 | 16 | 2018 |
Gene editing for duchenne muscular dystrophy using the CRISPR/Cas9 Technology: the Importance of fine-tuning the approach JP Tremblay, JP Iyombe-Engembe, B Duchêne, DL Ouellet Molecular Therapy 24 (11), 1888-1889, 2016 | 11 | 2016 |